Radiomics-based Non-invasive Classifier Research for HCC-related Liver Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-07-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to establish a non-invasive radiomics method to filter high recurrent-risk liver transplantation recipient population

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)

NCT07059936

Hepatocellular Carcinoma (HCC)

RECRUITING

By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation

NCT03880721

Hepatocellular Carcinoma

UNKNOWN

Liquid Biopsy-based Monitoring System for Relapse of HCC After Liver Transplantation: A Multi-center and Prospective Study

NCT03708705

Hepatocellular Carcinoma

UNKNOWN

Radiomics for Diagnosing Liver Diseases and Evaluating Progression

NCT03221049

Hepatitis B / Liver Space-occupying Lesions / Patients After Ablation

UNKNOWN

Clinical Application of Quantitative Major Imaging Features of CEUS LI-RADS

NCT06590948

Liver Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatocellular carcinoma is one of the most common malignant tumors in the world with high incidence and mortality. Liver transplantation is the most effective treatment for HCC and is in high demand in China. However, recurrence of HCC among liver transplantation recipients is still a great challenge and threat to the survival of recipients. So it is of great significance to establish a non-invasive way to filter high liver transplantation recipient population before transplantation. Based on large scales of pre-treatment MR images, the investigator's study aims to establish a non-invasive radiomics method to filter high recurrent-risk liver transplantation recipient population. This study will contribute to the precise selection of HCC-related liver transplantation recipients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma Liver Transplantation Magnetic Resonance Imaging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Relapse

Relapse of tumor within two years after liver transplantation

Risk model of tumor relapse

Intervention Type OTHER

High risk factor model of tumor relapse after liver transplantation

Non-relapse

Non-relapse of tumor within two years after liver transplantation

Risk model of tumor relapse

Intervention Type OTHER

High risk factor model of tumor relapse after liver transplantation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Risk model of tumor relapse

High risk factor model of tumor relapse after liver transplantation

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Risk model

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients had postoperative pathological diagnosis of HCC
* All patients had underwent contrast-enhanced MRI scan within 2 weeks before liver transplantation

Exclusion Criteria

* patients whose pathological diagnosis is not HCC
* patients whose CT images were affected by strong imaging artifacts, i.e. artifacts obscuring more than 10% of whole volume of interest
* patients whose clinical data or CT images were missing

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No